These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6669732)

  • 1. [Primary hyperlipoproteinemia from its clinical and laboratory aspects. V. Evaluation of circulatory hemodynamics based on the measurements of systolic time intervals and the physical analysis of blood circulation].
    Olejak B; Szmatłoch E; Brzeźniak R; Gregorczyk J; Pieczul-Mróz J; Jankowska E; Jagła A
    Przegl Lek; 1983; 40(11):797-801. PubMed ID: 6669732
    [No Abstract]   [Full Text] [Related]  

  • 2. [Primary hyperlipoproteinemia from its clinical and laboratory aspects. VI. Evaluation of arterial elasticity based on the physical analysis of blood circulation].
    Szmatłoch E; Olejak B; Gregorczyk J; Pieczul-Mróz J; Jagła A; Kutrzeba J; Cwajda H
    Przegl Lek; 1983; 40(11):803-6. PubMed ID: 6669733
    [No Abstract]   [Full Text] [Related]  

  • 3. [Primary hyperlipoproteinemias. Clinical, biological and physiopathological aspects].
    Bakir R; Chanu B; Rouffy J
    Pathol Biol (Paris); 1983 Apr; 31(4):248-58. PubMed ID: 6346238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of lipoprotein disorders.
    Lloyd JK
    Ric Clin Lab; 1982; 12(1):97-100. PubMed ID: 7089428
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biomicroscopy of the bulbar conjunctival vessels in various types of hyperlipoproteinemia].
    Piatin MM; Chekhova SP; Nikolaeva AA; Lineĭtseva LI
    Ter Arkh; 1982; 54(1):49-51. PubMed ID: 7079993
    [No Abstract]   [Full Text] [Related]  

  • 6. [Primary hyperlipoproteinemia in its clinical and laboratory aspects. IV. Blood coagulation and fibrinolysis indicators].
    Borodin M; Jurek D; Gregorczyk J; Pieczul-Mróz J; Cwajda H
    Przegl Lek; 1983; 40(10):727-32. PubMed ID: 6665208
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hyperlipoprotein phenotypes as risk factors in ischemic cardiopathy. II. Clinical aspects].
    Walter-Rosianu A
    Rev Pediatr Obstet Ginecol Pediatr; 1984; 33(2):145-60. PubMed ID: 6429817
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical aspects of hyperlipoproteinemia (author's transl)].
    Kaffarnik H; Schneider J
    Ther Umsch; 1980 Nov; 37(11):973-9. PubMed ID: 7455962
    [No Abstract]   [Full Text] [Related]  

  • 9. [Primary hyperlipoproteinemia in its clinical and laboratory aspects. VII. Phonoangiographic study].
    Szmatłoch E; Olejak B; Gregorczyk J; Pieczul-Mróz J; Brzeźniak R; Ansilewski K; Jagła A; Kutrzeba J
    Przegl Lek; 1984; 41(2):213-6. PubMed ID: 6739839
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hyperlipoproteinemias as risk factors for ischemic cardiopathy: new diagnostic possibilities].
    Gaddi A; Scaramuzzino G; Benassi MS; Aluigi L; Ceredi C; Albertazzi I; Suffritti G; Descovich GC
    Boll Soc Ital Cardiol; 1978; 23(9):1537-44. PubMed ID: 553627
    [No Abstract]   [Full Text] [Related]  

  • 11. The hyperlipoproteinemias.
    Whayne TF
    J Fam Pract; 1980 Nov; 11(5):789-99. PubMed ID: 7430980
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipoprotein protein receptors and their relation to atherosclerosis.
    Nestel PJ
    Circ Res; 1980 Jun; 46(6 Pt 2):I106-9. PubMed ID: 6991149
    [No Abstract]   [Full Text] [Related]  

  • 13. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V; Klör HU; Wechsler JG; Ditschuneit H
    J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Insulinemia in patients with hyperlipoproteinemia type IIa and V].
    Młyński J
    Kardiol Pol; 1981; 24(9):605-9. PubMed ID: 7029111
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of amounts of coronary arterial narrowing in patients with types II and IV hyperlipoproteinemia and in those with known normal lipoprotein patterns.
    Cabin HS; Roberts WC
    Am Heart J; 1981 Jan; 101(1):52-8. PubMed ID: 7457340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary hyperlipoproteinemia type IV and V in 3 young children].
    Karczewska K; Bobilewicz D; Kasner J; Smigla K; Torbus O; Sliwa F
    Pediatr Pol; 1980 Dec; 55(12):1331-9. PubMed ID: 7243406
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cholesterol and triglyceride plasma levels in patients with primary hyperlipoproteinemia. Decline after short-term i.v. glucagon administration].
    Andĕl M; Brodan V; Kucerová L; Grafnetter D; Kuhn E; Veselková A
    Cas Lek Cesk; 1980 May; 119(22):616-21. PubMed ID: 7427980
    [No Abstract]   [Full Text] [Related]  

  • 20. [Phenotype change in hyperlipoproteinemias].
    Meincke H
    Dtsch Z Verdau Stoffwechselkr; 1985; 45(5):236-9. PubMed ID: 4085393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.